Via News Knowledge File

AstraZeneca AB

organization80% conf.·synced Aug 13, 2026

Pharmaceutical company with license agreement with Insmed

sourced metrics

409

relationships

stated objectives

Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Dividend Per Share

1.06USD

Jul 27, 2026source

Revenue

30595USD

Jul 27, 2026source

Eps

1.61USD

Jul 27, 2026source

Stock Price

168.90USD

Jul 17, 2026source

Stock Return 7day

-0.6percent

Apr 1, 2026source

Valuation Score

3out_of_6

Apr 1, 2026source

Intrinsic Value Dcf

238.68USD

Apr 1, 2026source

Stock Return 30day

5.2percent

Apr 1, 2026source

Stock Return 1year

54.8percent

Apr 1, 2026source

Free Cash Flow

9.49USD

Apr 1, 2026source

Stock Return Ytd

12.1percent

Apr 1, 2026source

Projected Free Cash Flow

20.16USD

Apr 1, 2026source

Marathon Holding Pct Aum

2.9percent

Mar 31, 2026source

Marathon Holding Value

12.85USD

Mar 31, 2026source

Return 1month

-9.0percent

Mar 1, 2026source

Return 1year

21.8percent

Mar 1, 2026source

Analyst Price Target

165.33GBP

Mar 1, 2026source

Free Cash Flow Projected

20.2USD

Mar 1, 2026source

Stated objectives

Reach $80bn in annual sales by 2030

source

target: 80 billion USD by 2030-01-01 00:00:00stated

Achieve operating margin in mid-thirties percent range

source

target: 35 percent stated

High single digit revenue growth for 2025 on constant currency basis

source

target: 7-9 percent by 2025-01-01 00:00:00stated

Low double digit growth in adjusted earnings per share for 2025 on constant currency basis

source

target: 10-12 percent by 2025-01-01 00:00:00stated

Increase total revenue by mid-to-high single-digit percentage for FY 2026 at constant exchange rates

source

target: mid-to-high single-digit percentage growth by 2026-12-31 00:00:00stated

Increase core EPS by low double-digit percentage for FY 2026 at constant exchange rates

source

target: low double-digit percentage growth by 2026-12-31 00:00:00stated

Invest $15 billion in China through 2030 to expand medicines manufacturing and R&D

source

target: $15 billion by 2030-12-31 00:00:00stated

Complete more than 20 Phase 3 trial readouts in 2026

source

target: 20+ Phase 3 readouts by 2026-12-31 00:00:00stated

Obtain FDA approval for baxdrostat as first-in-class aldosterone synthase inhibitor for hard-to-control hypertension

source

target: regulatory approval stated

Advance portfolio of medicines for organ protection by slowing or stopping disease progression, paving way towards regenerative therapies in CVRM

source

stated

Relationship graph · 409 connections

Developed by

145

Competes with

Employs

Partnered with

located in

headquartered in

contracted by

acquired by

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →